HIGHLIGHTS
- who: Riccardo Bomben from the School University of di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy have published the paper: Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study, in the Journal: (JOURNAL) of 12/09/2022
SUMMARY
Consistently, del17p was independent predictor in multivariable models for OS/ PFS (P=0.0209, OS; P=0.0057, PFS; Model 1 Supplementry Table S2). At baseline, before ibrutinib treatment, the authors identified a total of 296 TP53 mutations in 126 patients (median mutations per patient: 1 . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.